
Can we move TLSs from biomarkers of response to active therapeutic tools? Harnessing cDC1 reprogramming to engineer immunogenic tertiary lymphoid structures within tumors may help answer that question. Exciting opportunities ahead!#TLSs #CellularReprogramming #CancerImmunotherapy








